Vaccines and Senior Travellers
- PMID: 35822022
- PMCID: PMC9261415
- DOI: 10.3389/fragi.2021.677907
Vaccines and Senior Travellers
Abstract
Background: International tourist travel has been increasingly steadily in recent years, and looks set to reach unprecedented levels in the coming decades. Among these travellers, an increasing proportion is aged over 60 years, and is healthy and wealthy enough to be able to travel. However, senior travellers have specific risks linked to their age, health and travel patterns, as compared to their younger counterparts. Methods: We review here the risk of major vaccine-preventable travel-associated infectious diseases, and forms and efficacy of vaccination for these diseases. Results: Routine vaccinations are recommended for older persons, regardless of whether they travel or not (e.g., influenza, pneumococcal vaccines). Older individuals should be advised about the vaccines that are recommended for their age group in the framework of the national vaccination schedule. Travel-specific vaccines must be discussed in detail on a case-by-case basis, and the risk associated with the vaccine should be carefully weighed against the risk of contracting the disease during travel. Travel-specific vaccines reviewed here include yellow fever, hepatitis, meningococcal meningitis, typhoid fever, cholera, poliomyelitis, rabies, Japanese encephalitis, tick-borne encephalitis and dengue. Conclusion: The number of older people who have the good health and financial resources to travel is rising dramatically. Older travellers should be advised appropriately about routine and travel-specific vaccines, taking into account the destination, duration and purpose of the trip, the activities planned, the type of accommodation, as well as patient-specific characteristics, such as health status and current medications.
Keywords: immunization; older adults; seniors 65 and over; travel; vaccines.
Copyright © 2021 Ecarnot, Maggi, Michel, Veronese and Rossanese.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Vaccinations for international travellers travelling from Greece.Travel Med Infect Dis. 2013 Jul-Aug;11(4):225-30. doi: 10.1016/j.tmaid.2012.11.007. Epub 2013 Feb 20. Travel Med Infect Dis. 2013. PMID: 23433917
-
[Travel vaccinations].Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020 Jan;63(1):74-84. doi: 10.1007/s00103-019-03064-z. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020. PMID: 31802155 Review. German.
-
[Vaccinations for overseas travelers--new evidence and recommendations].Ther Umsch. 2001 Jun;58(6):362-6. doi: 10.1024/0040-5930.58.6.362. Ther Umsch. 2001. PMID: 11441696 Review. German.
-
Vaccines for Older Travelers.Interdiscip Top Gerontol Geriatr. 2020;43:158-181. doi: 10.1159/000504492. Epub 2020 Apr 9. Interdiscip Top Gerontol Geriatr. 2020. PMID: 32305985 Review.
-
Current immunizations for travel.Curr Opin Infect Dis. 2003 Oct;16(5):369-74. doi: 10.1097/00001432-200310000-00001. Curr Opin Infect Dis. 2003. PMID: 14501987 Review.
Cited by
-
Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond.Immun Ageing. 2021 Oct 9;18(1):38. doi: 10.1186/s12979-021-00249-6. Immun Ageing. 2021. PMID: 34627326 Free PMC article. Review.
-
[After the COVID-19 pandemic-Which new vaccinations for adults are available or coming soon?].Inn Med (Heidelb). 2024 Jan;65(1):79-85. doi: 10.1007/s00108-023-01640-9. Epub 2023 Dec 18. Inn Med (Heidelb). 2024. PMID: 38108878 Review. German.
-
Immunogenicity and Safety of Pneumococcal Vaccines Co-Administered with Common Travel Vaccines in Adults: A Systematic Review.Vaccines (Basel). 2025 Jun 14;13(6):643. doi: 10.3390/vaccines13060643. Vaccines (Basel). 2025. PMID: 40573974 Free PMC article. Review.
References
-
- Ansaldi F., Bacilieri S., Durando P., Sticchi L., Valle L., Montomoli E., et al. (2008). Cross-protection by MF59-Adjuvanted Influenza Vaccine: Neutralizing and Haemagglutination-Inhibiting Antibody Activity against A(H3N2) Drifted Influenza Viruses. Vaccine 26, 1525–1529. 10.1016/j.vaccine.2008.01.019 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources